Balancing Treatment Intervals and Quality of Life in Myeloma | Anna Fleischer | #ASH24

Balancing Treatment Intervals and Quality of Life in Myeloma | Anna Fleischer | #ASH24
Early Relapse Score in Multiple Myeloma | Meral Beksac, MD | #ASH24
Trial of Iberdomide, A Novel CELMoD, In Smoldering Multiple Myeloma | Nisha Joseph, MD | #ASH24
MRD2STOP: Can multiple myeloma patients stop treatment? | Ben Derman, MD | #ASH24
Lovesick: Examining Couples Health During Myeloma Transplant | Ashley Rosko, MD | #ASH24
Cytomegalovirus Reactivation in Myeloma Patients on Teclistamab | Francesca Cottini, MD | #ASH24
Real-World Outcomes of Monoclonal Gammopathy of Renal Significance | Francesca Cottini, MD | #ASH24
Update on BMS-986393, a GPRC5D #Myeloma CAR-T | Susan Bal, MD | #ASH24
Addressing Socioeconomic Challenges in Acute Myeloid Leukemia Treatment | Mohamed Sorror, MD | #ASH24
Daratumumab vs Lenalidomide As Myeloma Maintenance Therapy | Sridevi Rajeeve, MD | #ASH24
What is MGUS?
MRD Progress in Newly Diagnosed #Myeloma, Quad Induction Therapy and ASCT |Luciano Costa, MD| #ASH24